Ö±³¦¼²²¡/Íâ¿ÆÊÖÊõ,rectal diseases/surgeryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÎÞË®ÒÒ´¼×¢Éä,percutaneous ethanol injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÆêѪ½¬,umbilical cord plasmaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸Îϸ°ûÁö,HepatomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÒÐÔÁܰ͹ÜÁö,cystic lymphangiomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÅèÇ»×ÔÖ÷Éñ¾­´Ô,Pelvic autonomic nerve Plexus(PANP)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾Æ¾«×¢Éä,Percutaneous ethanol injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« δ·Ö»¯°©,Undifferentiated carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ê®¶þÖ¸³¦Ö×Áö/Íâ¿ÆÑ§,Duodenal Neoplasms/surgÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ê®¶þÖ¸³¦Ö×Áö/Õï¶Ï,Duodenal Neoplasms/diagÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µÍ·Ö»¯,Poorly differentiatedÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾Ö²¿Ö×Áö¸´·¢,Local neoplasm recurrenceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½áÖ±³¦Ö×Áö/Á÷Ðв¡Ñ§,colorectal neoplasms/epidemiologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°û·¦Ñõ,Cell hypoxiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Eca109ϸ°ûϵ,Eca109 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾ÛÏÙÜÕ¶þÁ×ËáºËÌǾۺÏø-1,poly(ADP-ribose) polymerase-1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ê®¶þÖ¸³¦°©,Duodenal carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« DNAÖÜÆÚ,DNA cycleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« θµ×êÚÃŰ©,gastrocardiac carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈýÆÚɨÃè,Tri-phase scanningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ñÐÔ¹£×è,Malignant obstructionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« θÖ×Áö/·ÅÉäÁÆ·¨,stomach neoplasms/radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« BRCA2µ°°×,BRCA2 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍßÌØºø¸¹,Vater's ampullaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÓÕ²¶ÊÜÌå3,Decoy receptor 3Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« hOGG1»ùÒò,hOGG1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ɽ²è,CamelliaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁÙ´²²¡ÀíÒòËØ,clinicopathologic factorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ªÒÆ¹æÂÉ,Metastatic ruleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÒ©Ãô,Anticancer sensitivityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« TECIA·¨,TECIA assayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÚÔ൰°×,Visceral proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈÈÐݿ˵°°×70¶àëĸ´ºÏÎï,Heat shock protein 70 peptide complexÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸Î¶ñÐÔÖ×Áö,Liver malignant tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉÏÏû»¯µÀ°©,upper digestive tract cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³¦Ö×Áö/²¡Àíѧ,Intestinal neoplasms/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉÏ賦µÀ,Upper gastrointestinal tractÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Survivin¿¹Ô­,Survivin antigenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Musashi-1»ùÒò,Musashi-1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °±»ùͪÎìËá,Aminolevulinic acidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ùÒò±í´ïоƬ,Gene expression chipsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« BGC-823ϸ°ûϵ,BGC-823 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Eca-109ϸ°ûϵ,Eca-109 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔçÆÚÖ±³¦°©,Early rectal cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« À»Î²Ö×Áö,appendiceal neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³¬·Ö¸î·ÅÁÆ,Hyperfractionated radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ʵÐÔ-¼ÙÈéÍ·×´Áö,solid-pseudopapillary tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô­·¢ÐÔ¸ÎÖ×Áö,Primary liver cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÒÐÔÖ×Áö,cystic tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÎÖ×Áö/ÖÐÒ©ÁÆ·¨,LIVER NEOPLASMS/TCD therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒÅ´«ÐÔ·ÇÏ¢ÈâÐԴ󳦰©,hereditary non-polyposis colorectal cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐØÎ¸,intrathoracic stomachÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ó¸òܶ¾ËØ,toad toxicationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÅÉäÁ£×Ó,Radioactive seedsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏµÄ¤×ªÒÆ,Mesorectal metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ¨µÀ×èÈû,Biliary obstructionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éú³¤ÒÖËØÊÜÌåÑÇÐÍ,somatostatin receptor subtypeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÔöÖ³ÒÖÖÆ,inhibition of cell proliferationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾â³Ý×´ÏÙÁö,Serrated adenomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ѪÇåÍÙÒºËá,sialic acidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÉÃ×Ì¿»ìÐü×¢ÉäÒº,carbon nanoparticles suspension injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ó¸Î°©,large hepatocellular carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« SGC7901ϸ°ûϵ,SGC7901 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ëÄ»ù¸¬°±õ£Ò칹ø,Peptidylprolyl isomeraseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« С·Ö×ÓÒÖÖÆ¼Á,small-molecule inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Sonichedgehog,Sonic hedgehogÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éñ¾­ÏµÍ³/²¡Àíѧ,nervous system/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« BGC823ϸ°û,BGC823 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« hTERTmRNA,hTERT mRNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢СȾɫÌåά³Öµ°°×2,minichromosome maintenance protein 2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒÅ´«Ò׸Ð,genetic susceptibilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« P27µ°°×ÖÊ,P27 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶¹¸ù¹Üʳͨ¿Ú·þÒº,Dougenguanshitong oral liquidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈËÔ­·¢ÐԸΰ©,Hepatocellular carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ùÖʽðÊôµ°°×ø-11,matrix metalloproteinase-11Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« θ°©×ªÒÆ,gastric cancer metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶¾ËØA,toxin AÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« MSH2»ùÒò,MSH2 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« θÖ×Áö/´úл,stomach neoplasms/metabolismÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐØÏÙà×ऺϳÉø,thymidylate synthaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« SW620ϸ°û,SW620 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 賦Ö×Áö/Õï¶Ï,Gastrointestinal Neoplasms/diagÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Í»±äÐÍp53»ùÒò,mutation p53 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« EPÊÜÌå,EP receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ¹ÜÇÖ·¸,Vascular invasionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« îÆ·ÅÉäÐÔÍ¬Î»ËØ,Yttrium radioisotopesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °©Ö¢»ùÒò×é½âÆÊ¼Æ»®,Cancer Genome Anatomy ProjectÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶¯ÂöÆÚ,arterial phaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½á³¦¸Ø¹ÜÎǺÏÊõ,coloanal anastomosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´Å¹²ÕñÀ©É¢¼ÓȨ³ÉÏñ,diffusion-weighted MR imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« PNP/Mep-dRϵͳ,PNP/Mep-dR suicide gene systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« PF·½°¸,PF regimenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½á³¦°©Ï¸°ûÖê,Colon cancer cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 9-˳ά¼×Ëá,9-cis-retinoic acidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Cyclin Eµ°°×,Cyclin E proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« hMLH1µ°°×,hMLH1 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« CDX2µ°°×,CDX2 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô­·¢¸Î°©,Primary liver cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Áܰ͹ܽþÈó,Lymphatic vessel invasionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô­·¢ÐÔС³¦Ö×Áö,primary small intestinal tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«